Marshall Wace LLP Cuts Position in Boston Scientific Corporation $BSX

Marshall Wace LLP lowered its stake in Boston Scientific Corporation (NYSE:BSX) by 5.7% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,497,657 shares of the medical equipment provider’s stock after selling 450,505 shares during the quarter. Boston Scientific accounts for approximately 0.9% of Marshall Wace LLP’s portfolio, making the stock its 10th largest position. Marshall Wace LLP owned approximately 0.51% of Boston Scientific worth $805,323,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of BSX. Norges Bank bought a new stake in Boston Scientific in the second quarter valued at $2,089,937,000. Edgewood Management LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at about $746,655,000. Bessemer Group Inc. increased its position in Boston Scientific by 14,391.8% in the 2nd quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock valued at $313,618,000 after buying an additional 2,899,653 shares in the last quarter. Vanguard Group Inc. raised its stake in Boston Scientific by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after buying an additional 2,545,381 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Boston Scientific by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock worth $1,070,387,000 after acquiring an additional 1,664,108 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on BSX shares. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Needham & Company LLC restated a “buy” rating and set a $121.00 price objective on shares of Boston Scientific in a report on Friday, October 17th. Barclays raised their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Robert W. Baird boosted their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a report on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $123.77.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. The trade was a 21.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 143,095 shares of company stock worth $14,228,950 in the last quarter. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 1.0%

Shares of NYSE:BSX opened at $97.59 on Friday. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The company has a market capitalization of $144.67 billion, a PE ratio of 52.19, a price-to-earnings-growth ratio of 1.99 and a beta of 0.67. The business has a fifty day moving average price of $99.28 and a two-hundred day moving average price of $102.13. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same period in the previous year, the firm earned $0.63 EPS. The firm’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.